“Nature as an Apothecary Chest” — Enveda Turns Wild Plants Into Medicine with AI
A new “star player” has emerged in biotech. Enveda has just achieved unicorn status, drawing attention for fusing ancient nature with modern computation. Its ambition: harness AI to discover potentially valuable drugs among millions of plants — many still untapped as medicinal sources.
Enveda doesn’t just hunt for “natural compounds” — it scans nature’s chemical diversity, detects patterns, and matches them with viral or inflammatory targets that could underpin new therapies. And this is not lab fantasy — it’s at the crossroads of bioinformatics, chemistry, and machine learning.
Today the company announced closing its Series D: Enveda raised $150 million, pushing it past unicorn valuation. Funds will expand its platform, preclinical candidate pipeline, and team.
Why does it matter? Because this combo — AI + natural products — could change the drug-discovery paradigm. Many historic drugs (aspirin, metformin, etc.) came from plants or natural substances — often by accident. Enveda bets on making serendipity systematic.
Of course, challenges loom: natural compounds are complex to synthesize, hard to standardize, and slow to validate for safety. But Enveda is already tackling them — with preclinical projects, first candidates, and clinical trials on the horizon. https://enveda.com/
